Evaluating Rapamycin Treatment in Alzheimer's Disease Using Positron Emission Tomography (ERAP)

Karolinska Institute

Status and phase

Completed

Phase 2

Phase 1

Conditions

Alzheimer Disease

Treatments

Drug: Sirolimus

Study type

Interventional

Funder types

Other

Identifiers

NCT06022068

2023-00611-01

Details and patient eligibility

About

This single-center, uncontrolled pilot study aims to evaluate the efficacy, safety, and tolerability of six months of intermittently dosed oral rapamycin (sirolimus) in subjects with early-stage Alzheimer's disease.

Fifteen participants will be recruited. Following a set of baseline measurements, all participants will receive a weekly oral dose of 7 mg rapamycin for six months. Participants will be continuously monitored for safety and side effects. At the termination of the treatment, follow-up measurements will be taken.

The primary endpoint will be change in cerebral glucose metabolism, measured using 18F labeled fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET).

In addition to the registered outcome measures this pilot trial will explore the feasibility of acquiring data on the effect of sirolimus treatment on age-related tissue changes in the body using a variety of imaging modalities, such as bone mineral density assessed using quantitative computed tomography, retinal structures assessed using optical coherence tomography, periodontal tissue assessed using MRI and FDG-PET, cardiac function assessed using MRI, vessel wall in large arteries using MRI and [18F]FDG PET.

Enrollment

14 patients

Sex

All

Ages

50 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Clinical diagnosis of mild cognitive impairment (MCI), or dementia of Alzheimer's type
Amyloid positivity established with either amyloid positron emission tomography or cerebrospinal fluid analysis.
For subjects with dementia, the disease should be in an early stage, operationalized as:
- Stage 4 (Mild dementia) or lower, according to the National Institute on Aging - Alzheimer's Association 2018 clinical staging criteria, AND
- Clinical Dementia Rating Scale (CDR) global score of 1 or lower, AND
- Montreal Cognitive Assessment (MoCA) score of ≥ 18 OR Rey Auditory Verbal Learning Test (RAVLT) >4 words after 30 minutes
Capable of giving, and has the capacity to give informed consent
Availability of a responsible study partner who can accompany the subject to all planned visits
Male or female between 50 and 80 years
Normal or clinically acceptable medical history, physical examination, and vital signs

Exclusion criteria

History of any major disease that may interfere with safe engagement in the intervention (especially severe liver or kidney disease, or uncontrolled diabetes).
Central nervous system infarct, infection, or focal lesions of clinical significance on MRI scans.
Fulfills any contraindication for the use of sirolimus as per the summary of product characteristics, including but not restricted to:
- Current or planned medication with a strong inhibitor of CYP3A4 or P-gp
- Current or planned medication with a strong inducer of CYP3A4 or P-gp
- Other current medications with known serious interaction risks with sirolimus
- Known allergy or hypersensitivity to sirolimus
Significant obesity
Untreated and clinically significant hyperlipidemia
Treatment with immunosuppressive medications within the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted), or chemotherapeutic agents for malignancy within the last 3 years
Major surgery within 3 months prior to the planned start of sirolimus treatment, OR has major surgery planned during the period of the trial.
Use of experimental medications for Alzheimer's or any other investigational medication or device within 60 days. Participants who have been involved in a monoclonal antibody study are excluded unless it is known that they were receiving placebo in that trial